Effect of vitamin D supplementation on inflammatory markers, liver function, lipid profile, body composition, and sonographic findings in patients with NAFLD
- Conditions
- non alcohlic fatty liver disease.Other diseases of liver
- Registration Number
- IRCT2013060411763N8
- Lead Sponsor
- Food Security Research Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion criteria were stable increases in AST and ALT greater than 50 U / L and metabolic syndrome, which includes waist circumference greater than 40 inches for men and greater than 35 inches for women, Triglycerides greater than or equal to 150 mg /dl, HDL less than 40 mg / dl for men and less than 50 mg/dl for women, Blood pressure greater than or equal to 85/135 mmHg, fasting blood glucose greater than or equal to 110 mg / dl. The participants in this study have not hepatitis C, B and Wilson disease and no history of chronic liver disease, a disease that affects the gallbladder and bile ducts. The absence of gestational, diabetes mellitus type 1 and 2, use of drugs affecting the levels of ALT (valproic acid, tamoxifen, HMG-COA reductase inhibitors, metformin, ACE 1 and ACER 1). They do not follow the diet and weight loss because weight loss effective vitamin d. Exclusion criteria included hospitalization, lack of cooperation in the study and with an acute illness.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The severity of fatty liver using abdominal ultrasound at baseline and end of study. Timepoint: Baseline and 10 weeks after intervention. Method of measurement: ultrasound.;AST and ALT liver enzymes. Timepoint: Baseline and 10 weeks after intervention. Method of measurement: Blood tests.
- Secondary Outcome Measures
Name Time Method Body composition. Timepoint: baseline and 10 weeks after intervention. Method of measurement: instrument body composition.;FBS. Timepoint: baseline and 10 weeks after intervention. Method of measurement: blood test.;Lipid profile. Timepoint: baseline and 10 weeks after intervention. Method of measurement: blood test.;CRP. Timepoint: baseline and 10 weeks after intervention. Method of measurement: blood test.